X0508 4 2024-01-03 0 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer 0 Common Stock, par value $0.00001 per share 2024-01-03 4 A 0 28334 0.00 A 188724 D Common Stock, par value $0.00001 per share 2024-01-03 4 F 0 18233 17.40 D 170491 D Common Stock, par value $0.00001 per share 2024-01-03 4 A 0 70000 0.00 A 240491 D Common Stock, par value $0.00001 per share 2024-01-03 4 F 0 30889 17.40 D 209602 D Common Stock, par value $0.00001 per share 2024-01-04 4 F 0 13872 18.58 D 195730 D Common Stock, par value $0.00001 per share 2024-01-04 4 S 0 15000 17.90 D 180730 D Stock Option (Right to Buy) 17.40 2024-01-03 4 A 0 155000 0.00 A 2025-01-03 2034-01-03 Common Stock 155000 155000 D The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal. Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price. 25% of the shares subject to the option will vest on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2024-01-04